Taysha Gene Therapies Inc (TSHA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Taysha Gene Therapies Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Taysha Gene Therapies Inc's ROI in the second quarter of 2026?
Taysha Gene Therapies Inc recorded a cumulative net loss of $-150 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -45.02%.
Within the Healthcare sector 431 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3377 to 3634.
Taysha Gene Therapies: A Balancing Act Between Talent Acquisition and Financial StrugglesIn the ever-evolving landscape of biotechnology, Taysha Gene Therapies, Inc. (NASDAQ: TSHA) has recently taken center stage for a series of significant moves that highlight both ambition and concern. On November 1, 2024, the company’s Compensation Committee granted stock options amounting to 157,000 shares to three new employees, a decision rooted in its 2023 Inducement Plan and guided by Nasdaq Listing Rule 5635(c)(4). This latest incentive follows a broader trend at Taysha, which has made multiple inducement grants this year to attract and retain talent amidst mounting financial difficulties.These grants are not merely administrative gestures; they are critical tools for biotechnology firms like Taysha that are navigating the dual challenges of recruitment and fiscal health. The company’s recent history paints a stark picture: a cumulative net loss of $114 million in the 12 months ending in the second quarter of 2024 has resulted in a staggering negative return on investment (ROI) of -128.04%. This performance places Taysha at a disadvantage compared to its peers in the healthcare sector, where 695 other companies boast significantly higher ROI figures.
Taysha Gene Therapies, a prominent clinical-stage biotechnology company specializing in adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), has made a significant announcement today. On August 1, 2024, the Compensation Committee of Taysha s Board of Directors approved the issuance of options to purchase a total of 356,000 shares of the company s common stock to two newly recruited employees. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan and are considered a material inducement to attract and retain talented individuals in accordance with Nasdaq Listing Rule 5635(c)(4).
Taysha Gene Therapies, a clinical-stage biotech company specializing in gene therapies for severe monogenic diseases of the central nervous system, has recently made significant announcements regarding its operations. On July 3, 2024, the company granted four new employees options to purchase 484,000 shares of its common stock as an inducement for their recruitment. Meanwhile, Taysha Gene Therapies faced considerable financial difficulties, incurring a net loss of $215 million during the 12-month period ending in the third quarter of 2023. This negative return on investment (ROI) of -1104.79% raises concerns about the company s financial stability and overall performance. Let s delve into these facts and assess their impact on Taysha Gene Therapies. Financial Challenges and Negative ROI: The company recorded a cumulative net loss of $215 million during the 12 months ending in the third quarter of 2023, resulting in an alarming negative ROI of -1104.79%. This signifies that for every dollar investors put into the company during that period, they lost over 11 times that amount. It is evident that Taysha Gene Therapies faced significant financial difficulties, which can cast doubts on its long-term viability and ability to deliver returns to shareholders. The extent of these financial challenges raises concerns about the company s financial management, strategic decisions, and market performance.
Introduction Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a prominent clinical-stage gene therapy company specializing in AAV-based gene therapies for central nervous system (CNS) monogenic diseases, has recently shared an update on its deprioritized pipeline programs. The company aims to provide further support and opportunities for the potential development of these programs in its ongoing efforts. Despite recording a cumulative net loss of $-215 million during the 12 months ending in the third quarter of 2023, resulting in a negative return on investment (ROI) of -1104.79%, Taysha Gene Therapies Inc shares continue to trade on the NASDAQ slightly above its 52-week average. The Deprioritized Pipeline Programs Taysha Gene Therapies Inc is committed to developing groundbreaking AAV-based gene therapies for the treatment of monogenic disorders of the CNS. However, due to various reasons such as limited resources, strategic focus adjustment, or lack of promising results in preclinical or clinical trials, some programs have been classified as deprioritized. Instead of altogether abandoning these programs and their potential, Taysha Gene Therapies Inc has sought to explore further options for their development.
Financial Statements
Taysha Gene Therapies Inc's II. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
